About 40 percent of head and neck cancer survivors do not return to work
the ONA take:
According to a study published in the journal Head & Neck, researchers from Jena University Hospitial and University Medical Centre in Germany have found that many survivors of head and neck cancer do not return to work.
For the exploratory study, researchers identified 55 head and neck cancer survivors no older than 60 years of age.
All participants completed a survey that included subscales from various health questionnaires. Results showed that the rate of employed patients decreased from 75% of patients prior to diagnosis to 33% at an average of 66.8 months following diagnosis.
Researchers found that current employment was associated with more difficult physical work prior to diagnosis, surgical treatment, and current risky consumption of alcohol.
The study also showed that unemployed survivors reported decreased functional and social well-being scores and increased depression scores.
The findings suggest that psychosocial variables were significantly associated to employment, but the authors note that further research is necessary to evaluate these relationships.
Many survivors of head and neck cancer do not return to work.
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
- Ruxolitinib Effective as Long-term Treatment Option for Polycythemia Vera
- Study Affirms Activity of Ibrutinib in Patients With R/R CLL With 17p Deletion
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- Longer Maintenance Therapy Duration May Improve Survival in Myeloma
- HRQoL Better Maintained With Pembrolizumab in Ipilimumab-refractory Melanoma
- Economic Evaluation of Obinutuzumab in Combination With Chlorambucil in First-line Treatment of Patients With Chronic Lymphocytic Leukemia in Spain
- MRD Assessment Improves PFS Prediction in Patients With CLL
- Cancer Patients Have Unrealistic Hopes When Entering Clinical Trials
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|